CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤治疗患者的发热性中性粒细胞减少处理策略
英文原题：Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies.
查看英文原题
Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
发热性中性粒细胞减少症（FN）在血液恶性肿瘤患者中很常见，包括造血细胞移植（HCT）受者和细胞治疗（如嵌合抗原受体（CAR）-T细胞治疗）受者。数十年来，及时的经验性抗生素使用一直是主要治疗手段，但随着对治疗相关感染风险的了解更加深入，“一刀切”的方法已不再被广泛接受。日益增长的抗菌药物耐药性是一个越来越严峻的临床挑战。在未确定感染的FN中，关于降阶梯使用广谱抗生素的不断演变的策略是特别受关注的领域。
展开英文摘要原文
Febrile neutropenia (FN) is common among hematologic malignancy patients, including recipients of hematopoietic cell transplantation (HCT) and cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy.
Prompt empiric antibiotic use has been the mainstay for decades but a "one-size-fits-all" approach is no longer broadly accepted, as treatment-related infectious risk are more understood. Growing antimicrobial resistance is an increasing clinical challenge. Evolving strategies on de-escalation of broad-spectrum antibiotics in FN without identified infection are areas of particular interest.
论文信息
- 作者
- Stohs EJ、Abbas A、Freifeld A
- 单位
- Division of Infectious Diseases, Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.United States
- 文献类型
- 综述
- 期刊
- Transplant infectious disease : an official journal of the Transplantation Society2024 Apr
- 原文标识
- PubMed 38349035 · DOI 10.1111/tid.14236